$77.36
Value $15.0B
BBIO and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$77.36
Value $15.0B
$282.55
Value $681B
BridgeBio Pharma (BBIO) has a market value of $15.0B and Johnson & Johnson (JNJ) $681B. Over the last year, with dividends, BBIO moved +16.5% and JNJ +47.5%. Dividend yield: BBIO none, JNJ 1.87%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
BBIO$15.0B
JNJ$681B
JNJ is 45 times BBIO
Revenue, 12 months
BBIO$946M
JNJ$99.3B
JNJ is 105 times BBIO
Net income, 12 months
BBIO-$566M
JNJ$16.1B
Operating margin
BBIO-38.5%
JNJ–
ROIC
BBIO-97.6%
JNJ12.4%
109.9 points apart
P/E
BBIO–
JNJ42.3
Dividend yield
BBIO0.0%
JNJ1.9%
1.9 points apart
5-year return
BBIO+60.6%
JNJ+98.6%
38.0 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
BBIO+60.6%
JNJ+98.6%
| Period | BBIOWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +16.5%Price +16.5% | +47.5%Price +44.2% |
| 3 years since November 16, 2023 | +168.1%+38.9% a yearPrice +168.1% | +105.0%+27.0% a yearPrice +88.2% |
| 5 years since November 15, 2021 | +60.6%+9.9% a yearPrice +60.6% | +98.6%+14.7% a yearPrice +72.8% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
BBIOBridgeBio PharmaJNJJohnson & Johnson
| Price | $77.36 | $282.55 |
|---|---|---|
| Market value | $15.0B | $681B |
| Enterprise value (EV) | $16.1B | $708B |
| P/E | – | 42.3 |
| P/E, 5-year median | – | 21.9 |
| P/B | – | 8.4 |
| EV/EBIT | – | 39.9 |
| Free cash flow yield | – | 3.0% |
| Revenue, 12 months | $946M | $99.3B |
|---|---|---|
| Net income, 12 months | -$566M | $16.1B |
| Free cash flow, 12 months | -$370M | $20.6B |
| Earnings per share, 12 months | -$3.03 | $6.59 |
| Revenue growth, year on year | 126.3% | 6.1% |
| Revenue growth a year, past | +127.4%over 5 years | +2.7%over 5 years |
| EPS growth a year, past | – | +14.9%over 5 years |
| Gross margin | 94.3% | 67.6% |
|---|---|---|
| Operating margin | -38.5% | – |
| Net margin | -59.8% | 16.2% |
| ROIC | -97.6% | 12.4% |
| ROE | – | 19.7% |
| Cash | $1.5B | $17.2B |
|---|---|---|
| Total debt | $2.6B | $44.7B |
| Net debt / EBITDA | – | 1.1 |
| Interest cover | -7.1× | 18.0× |
| Dividend yield | – | 1.9% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | 0.3% | 0.9% |
| Shareholder yield | 0.3% | 2.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($681B) is about 45.4 times BridgeBio Pharma ($15.0B), at today's prices.
Since November 15, 2021, BBIO's price moved +60.6% and JNJ's +72.8%. With dividends: BBIO +60.6% (+9.9% a year), JNJ +98.6% (+14.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for BridgeBio Pharma and 1.87% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
Over the last twelve months, the net margin was -59.8% for BridgeBio Pharma and 16.2% for Johnson & Johnson, and the operating margin -38.5% and –. Revenue was $946M and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.